Teva, Bausch & Lomb minoxidil hair growth generics tentatively approved; Upjohn files NDA for Rogaine 5%.
Executive Summary
TEVA, BAUSCH & LOMB FIRST TENTATIVE ANDAs FOR ROGAINE EQUIVALENTS have a potential full approval date of Feb. 13, when Pharmacia & Upjohn's patent for the hair loss treatment Rogaine (minoxidil 2% solution) expires. Teva's Lemmon generic subsidiary received the first tentative ANDA approval for topical minoxidil on Dec. 15; Bausch & Lomb Pharmaceuticals received its tentative approval on Dec. 22.